Welcome to our dedicated page for SILENCE THERAPEUTICS ORD news (Ticker: SLNCF), a resource for investors and traders seeking the latest updates and insights on SILENCE THERAPEUTICS ORD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SILENCE THERAPEUTICS ORD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SILENCE THERAPEUTICS ORD's position in the market.
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) has announced the appointment of
The report titled "Polycythemia Vera Market Insights, Epidemiology, and Market Forecast -2032" offers a comprehensive analysis of the Polycythemia Vera market. In 2022, the U.S. Polycythemia Vera market size was approximately USD 1,500 million and is projected to grow through 2032. The report highlights that PharmaEssentia's Besremi is the only first-line therapy approved, while Incyte's Jakafi is the sole second-line treatment. Additionally, competition may arise from Protagonist Therapeutics' Rusfertide and Imago Biosciences' Bomedemstat, expected to launch in late 2024 and 2026 respectively. The report also discusses emerging therapies with potential market impact, including Silence Therapeutics' SLN124.
The Global Small Interfering RNA (SiRNA) Market is projected to reach $964.17 Million by 2030, with a CAGR of 8.6% from 2023 to 2030. Key insights show that liposome-based systemic therapy represents 52.01% of the market share. The cancer segment leads therapeutics with a 38.14% share, while research institutions account for 43.07% of applications. North America dominated the market in 2022 due to robust R&D activities. Significant partnerships, such as Silence Therapeutics with Hansoh Pharmaceutical, are accelerating market growth in the APAC region. The report emphasizes a focus on RNA functions and its therapeutic potential for various genetic disorders.
FAQ
What is the market cap of SILENCE THERAPEUTICS ORD (SLNCF)?
